

Hepatokines as a Link between Obesity and Cardiovascular Diseases

Hye Jin Yoo, Kyung Mook Choi

Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea

Non-alcoholic fatty liver disease, which is considered a hepatic manifestation of metabolic syndrome, independently increases the risks of developing cardiovascular disease (CVD) and type 2 diabetes mellitus. Recent emerging evidence suggests that a group of predominantly liver-derived proteins called hepatokines directly affect the progression of atherosclerosis by modulating endothelial dysfunction and infiltration of inflammatory cells into vessel walls. Here, we summarize the role of the representative hepatokines fibroblast growth factor 21, fetuin-A, and selenoprotein P in the progression of CVD.

Keywords: Fetuin-A; Fibroblast growth factor 21; Hepatokines; Non-alcoholic fatty liver disease; Selenoprotein P

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of progressive liver diseases, including simple steatosis, non-alcoholic steatohepatitis, fibrosis, and eventually cirrhosis, in the absence of excessive alcohol consumption [1] and has been considered a hepatic manifestation of metabolic syndrome. NAFLD is a marker of pathologic ectopic fat accumulation combined with a low-grade chronic inflammatory state [2]. The liver is a pivotal visceral organ with respect to fat accumulation. Accumulation of lipid droplets decreases the efficacy of insulin signaling. Hepatic lipids also induce endoplasmic reticulum stress, leading to activation of c-Jun N-terminal kinases and nuclear factor κ B (NF- κ B), two major regulators of inflammatory pathways that can inhibit phosphorylation of insulin receptor substrate-1 [3]. Recent evidence suggests that NAFLD is an emerging risk factor for cardiovascular disease (CVD) independent of traditional CVD risk factors, implying that NAFLD might be directly involved in CVD pathogenesis. Here, we will summarize the relationship between NAFLD and CVD, focusing on the causative

roles of liver-derived hepatokines in the progression of CVD (Fig. 1).

EPIDEMIOLOGIC STUDIES LINKING NAFLD TO CVD

A recent comprehensive systematic review of 27 studies showed that NAFLD is associated with subclinical atherosclerosis independent of traditional risk factors and metabolic syndrome and across a wide range of ethnicities [4]. In that review, 14 among a total of 16 studies that examined the association of NAFLD with carotid intima media thickness (CIMT) demonstrated a significant increase in the mean CIMT in individuals with NAFLD compared to healthy people, even after adjusting for other confounding variables [4]. Using multislice computed tomography, Akabame et al. [5] showed that liver fat was significantly related to the presence of vulnerable plaques with a lipid core. Furthermore, Villanova et al. [6] reported that brachial artery flow-mediated dilatation (FMD), representing endothelial dysfunction, was reduced by 48% in subjects with NAFLD and that

Corresponding author: Kyung Mook Choi
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 152-703, Korea
E-mail: medica7@gmail.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.




Fig. 1. Underlying mechanism connecting non-alcoholic fatty liver disease (NAFLD) to cardiovascular disease (CVD). LDL, low density lipoprotein; HDL, high density lipoprotein; hsCRP, high-sensitivity C-reactive protein; PAI-1, plasminogen activator inhibitor-1; FGF-21, fibroblast growth factor 21.

NAFLD predicted a reduced FMD (odds ratio [OR], 6.7; 95% confidence interval [CI], 1.26 to 36.1) after adjusting for age, sex, body mass index, and insulin resistance.

Several large cross-sectional and prospective studies showed that NAFLD was associated with an increased prevalence of CVD and the incidence of cardiovascular (CV) events irrespective of other CVD risk factors. In 2,839 patients with type 2 diabetes mellitus (DM), those with NAFLD had a higher prevalence of coronary, cerebrovascular, and peripheral vascular disease than their counterparts without NAFLD, independent of conventional CVD risk factors, medication history, and DM-related variables [7]. In addition, during a median 7.3 years of follow-up, an elevated baseline level of serum γ -glutamyl transferase, a surrogate marker for hepatic steatosis, was significantly associated with increased risk of all-cause and CVD mortality in men, even after adjusting for other metabolic risk factors [8]. Therefore, these studies suggested that assessment of NAFLD might be a helpful approach to more accurate and early CVD risk stratification.

MECHANISMS CONNECTING NAFLD WITH CVD

The underlying mechanism by which NAFLD increases the risk of CVD has not been clarified; moreover, whether NAFLD is an independent risk factor for CVD or simply a risk marker that coexists in people at increased risk of CVD is still controversial. The potential mechanism by which NAFLD increases CVD risk is based on the development of inflamed visceral adipose

tissue [9], which is the main source of an elevated flux of free fatty acids (FFAs) into the portal vein for direct transport to the liver and subsequent hepatic fat accumulation [10]. Therefore, NAFLD can be considered a sensitive marker of pathological dysfunction of visceral adipose tissue that is more relevant to CV outcome than simply adipose tissue mass.

On the other hand, hepatic steatosis itself leads to intrahepatic inflammation through activation of NF- κ B pathways that exacerbate insulin resistance both locally in the liver and systemically. The liver of subjects with NAFLD might release a variety of proatherogenic, proinflammatory, and diabetogenic mediators such as high-sensitivity C-reactive protein (hsCRP), fibrinogen, and plasminogen activator inhibitor-1 (PAI-1), which have important roles in the development of CVD [1]. hsCRP, which is primarily produced by the liver and is a marker of inflammation, was an independent predictor of CV events in several large studies [11]. Similarly, fibrinogen and PAI-1 also originate from hepatic tissue and are activators of the coagulation system thus enhancing atherothrombosis [2], suggesting that an increase in liver-secreted factors in NAFLD plays an important role in the pathogenesis of systemic inflammation and atherosclerosis. Therefore, the liver functions as an inducer of systemic inflammation as well as a target organ of various inflammatory reactions that occur within dysfunctional adipose tissue.

Recent evidence suggests that a group of predominantly liver-derived proteins called hepatokines directly affect glucose and lipid metabolism, similar to previously described adipokines and myokines [12]. At the present time, fetuin-A, fibroblast growth factor 21 (FGF-21), and selenoprotein P (SeP) are

considered representative hepatokines; however, there have been very limited studies exploring the direct function of these hepatokines on the development of CVD.

FIBROBLAST GROWTH FACTOR 21

FGF-21 is a 181-amino acid peptide hormone that is primarily secreted by the liver and acts as a potent metabolic regulator [13]. Expression of the human FGF-21 gene is mediated by peroxisome proliferator-activated receptor- α (PPAR- α) during starvation [14] and regulated by PPAR- γ after feeding [15]. Circulating FFAs, a characteristic feature of fasting, and different kinds of stress such as hepatic injury, chemical insult, and disease, stimulate secretion of FGF-21 into the circulation [16]. Administration of FGF-21 to animal models and humans has been shown to decrease body weight and levels of blood triglycerides and low density lipoprotein (LDL) cholesterol, and to improve insulin sensitivity. Mashili et al. [17] reported that FGF-21 treatment induced basal and insulin-stimulated glucose uptake in human skeletal muscle cells through upregulation of glucose transporter-1. Very recently, a randomized phase 1 clinical trial showed that treatment with LY2405319, an analog of FGF-21, produced significant improvements in dyslipidemia of obese human subjects with type 2 DM [18]. FGF-21 stimulates lipolysis in the diabetic *db/db* mouse and obese humans, and individuals with a cluster of metabolic disorders have increased serum FGF-21 levels [19] to compensate for the abnormal metabolic status.

Early studies on FGF-21 focused on its role as a metabolic hormone during fasting or starvation. More recent studies have indicated a possible role of FGF-21 in CVD. Planavila et al. [20] demonstrated that FGF-21 knockout mice exhibited increased cardiac mass and impaired cardiac function, which could be ameliorated by treatment with FGF-21, suggesting its protective role against hypertrophic insults. Furthermore, FGF-21 infusion into a rat heart significantly recovered cardiac function following myocardial infarction [21]. In cultured rodent cardiac microvascular endothelial cells, FGF-21 expression was upregulated when the cells were incubated with oxidized LDL, indicating that FGF-21 might be secreted by endothelial cells in response to stress and that elevated levels may be a signal of endothelial cell injury [22]. In accordance with these animal studies, elevated serum FGF-21 levels are associated with carotid atherosclerosis in humans, independent of established CVD risk factors [23]. Multivariate logistic regression analysis also

identified serum FGF-21 level as one of the independent factors of coronary artery disease occurrence (OR, 2.98; 95% CI, 1.014 to 8.786; $P < 0.05$) [24]. Furthermore, we previously reported that brachial-ankle pulse wave velocity reflecting arterial stiffness had a significant positive correlation with circulating FGF-21 levels [25]. Therefore, FGF-21 may be an attractive target for the diagnosis and treatment of obesity and related diseases, including CVD.

FETUIN-A

Fetuin-A is a 64-kDa phosphorylated glycoprotein that is primarily synthesized by hepatocytes [26]. Fetuin-A is a natural inhibitor of the insulin receptor tyrosine kinase, leading to insulin resistance in rodents [27]. Apart from its direct effects on the insulin receptor, fetuin-A promotes insulin resistance by propagating a proinflammatory state. Fetuin-A treatment aggravates proinflammatory cytokine expression while reducing adiponectin expression in both adipocytes and monocytes [28]. Furthermore, incubation of HepG2 cells or rat hepatocytes with palmitate stimulates binding of NF- κ B to the fetuin-A promoter, thereby augmenting fetuin-A synthesis and secretion [29]. We previously reported that palmitate-induced fetuin-A stimulated triacylglycerol accumulation in hepatocytes and that adiponectin inhibited palmitate-induced hepatic fetuin-A expression through the adenosine monophosphate-activated protein kinase (AMPK) pathway [30]. These results suggest that fetuin-A might directly cause insulin resistance and modulate inflammatory reactions, leading to various metabolic disturbances. Consistent with these findings, many epidemiologic studies have observed elevated levels of circulating fetuin-A in obesity and related metabolic diseases including type 2 DM, metabolic syndrome, and NAFLD [31-33]. Our previous study showed a significant decrease in circulating fetuin-A levels after 12 weeks of caloric restriction that was accompanied by improvements in visceral fat area, blood pressure, lipid profiles, and glucose levels [34]. In the European Prospective Investigation into Cancer and Nutrition-Potsdam study, plasma fetuin-A levels were positively associated with the incidence of diabetes after adjustment for sex, body mass index, waist circumference, and lifestyle risk factors during 7 years of follow-up [35].

However, the relationship between circulating fetuin-A and CVD risk appears to be more complicated. Fetuin-A can bind with Ca^{2+} , inhibiting ectopic calcification [36]. In studies examining patients with chronic kidney diseases, fetuin-A level is inversely associated with calcification scores, CV events, and

CV mortality [37]. Nondiabetics with a higher fetuin-A level have decreased risks of incident CVD and CVD-related mortality, whereas type 2 diabetics with higher fetuin-A levels have increased risks of incident CVD and CVD-related mortality [38,39]. Possible mechanisms by which fetuin-A can promote atherosclerosis in CVD patients are through induction of insulin resistance and increased expression of cytokines in monocytes that participate in the inflammation. Siegel-Axel et al. [40] demonstrated that fetuin-A inhibited the proliferation of perivascular fat cells and increased the expression of proinflammatory cytokines including interleukin-8, interleukin-6, monocyte chemoattractant protein-1, and PAI-1 in these cells. Further studies should be performed to determine the exact function of fetuin-A in CVD according to the diverse underlying patient conditions.

SELENOPROTEIN P

SeP, a 42-kDa glycoprotein, is produced in the liver and secreted into plasma [41]. SeP was recently identified as a hepatokine associated with insulin resistance in humans through serial analysis of gene expression [42]. Administration of SeP to mice decreased insulin signaling and glucose metabolism in both liver and skeletal muscle, whereas SeP-deficient mice showed enhanced insulin signaling and improved glucose tolerance [42]. In our previous studies, patients with type 2 DM and those with NAFLD had higher serum SeP levels than healthy controls [43,44]. Furthermore, we found that salsalate and adiponectin ameliorated palmitate-induced insulin resistance in hepatocytes by inhibition of SeP through the AMPK-Forkhead box protein O1 α (FOXO1 α) pathway [45], suggesting that SeP acting via the AMPK-FOXO1 α -dependent pathway might be a novel mechanism mediating the antidiabetic effects of salsalate and adiponectin.

However, there have been very few studies on the relationship of SeP with CVD. We first reported that circulating SeP level has an independent association with carotid intima-media thickness even after adjustment for other confounding factors [44]. Very recently, Ishikura et al. [46] showed that physiological concentrations of SeP inhibited vascular endothelial growth factor-stimulated cell proliferation, tubule formation, and migration in human umbilical vein endothelial cells, leading to impaired angiogenesis and delay of wound closure in mice overexpressing SeP. Further studies are needed to explore the direct relationship between SeP with CVD and the underlying mechanism.

CONCLUSIONS

Hepatokines that are mainly secreted from the liver are known to directly affect glucose and lipid metabolism. There is accumulating evidence that various hepatokines can modulate inflammatory processes that in turn mediate atherosclerotic process. Therefore, identification of novel hepatokines might allow the development of new strategies to diagnose and treat NAFLD-related metabolic disturbances, including CVD.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012006363, KMC and 2012R1A1A1005257, HJY), by the Brain Korea 21 Project of the Ministry of Education and Human Resources Development, Republic of Korea (KMC and SHB), and by a grant from Korea University (KMC).

REFERENCES

1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol* 2013;10:330-44.
2. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? *Eur Heart J* 2012;33:1190-200.
3. Byrne CD, Targher G. Ectopic fat, insulin resistance, and non-alcoholic fatty liver disease: implications for cardiovascular disease. *Arterioscler Thromb Vasc Biol* 2014;34:1155-61.
4. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD, Budoff MJ, Nasir K. A systematic review: burden and severity of subclinical cardiovascular disease among those with non-alcoholic fatty liver; should we care? *Atherosclerosis* 2013;230:258-67.
5. Akabame S, Hamaguchi M, Tomiyasu K, Tanaka M, Kobayashi-Takenaka Y, Nakano K, Oda Y, Yoshikawa T. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver dis-

- ease (NAFLD) by 64-detector multislice computed tomography (MSCT). *Circ J* 2008;72:618-25.
6. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. *Hepatology* 2005;42:473-80.
 7. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care* 2007;30:1212-8.
 8. Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister SE, Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. *Hepatology* 2009;50:1403-11.
 9. Badman MK, Flier JS. The adipocyte as an active participant in energy balance and metabolism. *Gastroenterology* 2007;132:2103-15.
 10. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. *Arteriosclerosis* 1990;10:493-6.
 11. Lavie CJ, Milani RV, Verma A, O'Keefe JH. C-reactive protein and cardiovascular diseases: is it ready for primetime? *Am J Med Sci* 2009;338:486-92.
 12. Stefan N, Haring HU. The role of hepatokines in metabolism. *Nat Rev Endocrinol* 2013;9:144-52.
 13. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crowley M, Fisher FM, Badman MK, Martinez-Chantar ML, Maratos-Flier E. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. *Gastroenterology* 2010;139:456-63.
 14. Galman C, Lundasen T, Kharitononkov A, Bina HA, Eriksson M, Hafstrom I, Dahlin M, Amark P, Angelin B, Rudling M. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. *Cell Metab* 2008;8:169-74.
 15. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. *Cell* 2012;148:556-67.
 16. Yu H, Xia F, Lam KS, Wang Y, Bao Y, Zhang J, Gu Y, Zhou P, Lu J, Jia W, Xu A. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. *Clin Chem* 2011;57:691-700.
 17. Mashili FL, Austin RL, Deshmukh AS, Fritz T, Caidahl K, Bergdahl K, Zierath JR, Chibalin AV, Moller DE, Kharitononkov A, Krook A. Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. *Diabetes Metab Res Rev* 2011;27:286-97.
 18. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitononkov A, Bumol T, Schilske HK, Moller DE. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. *Cell Metab* 2013;18:333-40.
 19. Dostalova I, Haluzikova D, Haluzik M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. *Physiol Res* 2009;58:1-7.
 20. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, Gabrielli LA, Sitges M, Giralt M, van Bilsen M, Villarroya F. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. *Nat Commun* 2013;4:2019.
 21. Patel V, Adya R, Chen J, Ramanjaneya M, Bari MF, Bhudia SK, Hillhouse EW, Tan BK, Randeva HS. Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. *PLoS One* 2014;9:e87102.
 22. Lu Y, Liu JH, Zhang LK, Du J, Zeng XJ, Hao G, Huang J, Zhao DH, Wang GZ, Zhang YC. Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells. *Chin Med J (Engl)* 2010;123:3417-21.
 23. Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH, Tse HF, Chau MT, Cheung BM, Lam KS. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. *Arterioscler Thromb Vasc Biol* 2013;33:2454-9.
 24. Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M, Lu Z, Gao M, Bao Y, Jia W. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. *Cardiovasc Diabetol* 2013;12:124.
 25. Yang SJ, Hong HC, Choi HY, Yoo HJ, Cho GJ, Hwang TG, Baik SH, Choi DS, Kim SM, Choi KM. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. *Clin Endocrinol (Oxf)* 2011;75:464-9.
 26. Nangami GN, Watson K, Parker-Johnson K, Okereke KO, Sakwe A, Thompson P, Frimpong N, Ochieng J. Fetuin-A (alpha2HS-glycoprotein) is a serum chemo-attractant that also promotes invasion of tumor cells through Matrigel. *Biochem Biophys Res Commun* 2013;438:660-5.
 27. Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnchen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. *Biochem J* 2003;376(Pt 1):135-45.

28. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. *PLoS One* 2008;3:e1765.
29. Dasgupta S, Bhattacharya S, Biswas A, Majumdar SS, Mukhopadhyay S, Ray S, Bhattacharya S. NF-kappaB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. *Biochem J* 2010;429:451-62.
30. Jung TW, Youn BS, Choi HY, Lee SY, Hong HC, Yang SJ, Yoo HJ, Kim BH, Baik SH, Choi KM. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A. *Biochem Pharmacol* 2013;86:960-9.
31. Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. *J Clin Endocrinol Metab* 2012;97:4717-23.
32. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG, Health ABCS. Fetuin-A and incident diabetes mellitus in older persons. *JAMA* 2008;300:182-8.
33. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. *Circulation* 2006;113:1760-7.
34. Choi KM, Han KA, Ahn HJ, Lee SY, Hwang SY, Kim BH, Hong HC, Choi HY, Yang SJ, Yoo HJ, Baik SH, Choi DS, Min KW. The effects of caloric restriction on fetuin-A and cardiovascular risk factors in rats and humans: a randomized controlled trial. *Clin Endocrinol (Oxf)* 2013;79:356-63.
35. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU, Schulze MB. Plasma fetuin-A levels and the risk of type 2 diabetes. *Diabetes* 2008;57:2762-7.
36. Mori K, Emoto M, Inaba M. Fetuin-A and the cardiovascular system. *Adv Clin Chem* 2012;56:175-95.
37. Evrard S, Delanaye P, Kamel S, Cristol JP, Cavalier E; SFBC/SN joined working group on vascular calcifications. Vascular calcification: from pathophysiology to biomarkers. *Clin Chim Acta* 2015;438:401-14.
38. Jensen MK, Bartz TM, Mukamal KJ, Djousse L, Kizer JR, Tracy RP, Ziemann SJ, Rimm EB, Siscovick DS, Shlipak M, Ix JH. Fetuin-A, type 2 diabetes, and risk of cardiovascular disease in older adults: the cardiovascular health study. *Diabetes Care* 2013;36:1222-8.
39. Laughlin GA, Cummins KM, Wassel CL, Daniels LB, Ix JH. The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study. *J Am Coll Cardiol* 2012;59:1688-96.
40. Siegel-Axel DI, Ullrich S, Stefan N, Rittig K, Gerst F, Klingler C, Schmidt U, Schreiner B, Randrianarisoa E, Schaller HE, Stock UA, Weigert C, Konigsrainer A, Haring HU. Fetuin-A influences vascular cell growth and production of proinflammatory and angiogenic proteins by human perivascular fat cells. *Diabetologia* 2014;57:1057-66.
41. Burk RF, Hill KE. Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeostasis. *Annu Rev Nutr* 2005;25:215-35.
42. Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S, Ishikura K, Ando H, Takeshita Y, Ota T, Sakurai M, Yamashita T, Mizukoshi E, Yamashita T, Honda M, Miyamoto K, Kubota T, Kubota N, Kadowaki T, Kim HJ, Lee IK, Minokoshi Y, Saito Y, Takahashi K, Yamada Y, Takakura N, Kaneko S. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. *Cell Metab* 2010;12:483-95.
43. Choi HY, Hwang SY, Lee CH, Hong HC, Yang SJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Increased selenoprotein p levels in subjects with visceral obesity and non-alcoholic fatty liver disease. *Diabetes Metab J* 2013;37:63-71.
44. Yang SJ, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. *J Clin Endocrinol Metab* 2011;96:E1325-9.
45. Jung TW, Choi HY, Lee SY, Hong HC, Yang SJ, Yoo HJ, Youn BS, Baik SH, Choi KM. Salsalate and adiponectin improve palmitate-induced insulin resistance via inhibition of selenoprotein P through the AMPK-FOXO1alpha pathway. *PLoS One* 2013;8:e66529.
46. Ishikura K, Misu H, Kumazaki M, Takayama H, Matsuzawa-Nagata N, Tajima N, Chikamoto K, Lan F, Ando H, Ota T, Sakurai M, Takeshita Y, Kato K, Fujimura A, Miyamoto K, Saito Y, Kameo S, Okamoto Y, Takuwa Y, Takahashi K, Kidoya H, Takakura N, Kaneko S, Takamura T. Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells. *Diabetologia* 2014;57:1968-76.